Latest News and Press Releases

BELGRADE, MT, June 19, 2018 (GLOBE NEWSWIRE) -- XtantTM Medical Holdings, Inc. (NYSE American: XTNT) announces that the subscription period for its previously announced rights offering (the...

Reports Pro Forma Stockholders’ Equity of approximately $47.4M as of 2/15/18Xtant has regained compliance with the NYSE American listing standards BELGRADE, Mont., Feb. 15, 2018 (GLOBE NEWSWIRE) --...

Exchange of $70.238M (plus interest) of convertible notes into 10,401,309 shares of common stock at $7.20 per share.$6.809M Private Placement representing 945,819 shares of common stock at $7.20 per...

Approval of the issuance of new shares of common stock, as required by the NYSE American.Approval of an amendment to its certificate of incorporation, enabling its previously announced 1:12 reverse...

Conversion of $1.627M (plus interest) of convertible notes into common stockExchange of $70.238M (plus interest) of convertible notes into common stockUpon stockholder approval, amendment of...

Company restructuring efforts continue to gain traction towards profitability Third Quarter 2017 Highlights Reported third quarter 2017 revenue of $19.8 million compared to $23.1 million reported...

BELGRADE, Mont., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative medicine products and medical devices, announced...

BELGRADE, Mont., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative medicine products and medical devices, today...

BELGRADE, Mont., Oct. 27, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative medicine products and medical devices, today...

BELGRADE, Mont., Oct. 25, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative medicine products and medical devices, announced it...